Yıl: 2019 Cilt: 35 Sayı: 4 Sayfa Aralığı: 224 - 229 Metin Dili: Türkçe DOI: 10.15312/EurasianJVetSci.2019.245 İndeks Tarihi: 01-04-2020

Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi

Öz:
Amaç: Bu araştırmanın birinci amacı koyunlara danofloksasin uygulamasının oksidatif stres biyobelirteci 8-hidroksi-2-deoksiguanozin (8-OHDG) üzerine etkisini belirlemektir. Ayrıca kalp [Troponin I, kreatin kinaz-MB (CK-MB) izoenzim, laktat dehidrogenaz (LDH), aspartat aminotransferaz (AST)], karaciğer [Alkalen fosfataz (ALP), alanin aminotransferaz (ALT)] ve böbrek [Kan üre nitrojen (BUN), kreatinin] hasar biyobelirteçleri ile hemogram [Akyuvar sayısı (WBC), alyuvar sayısı (RBC), platelet sayısı, hemoglobin, hematokrit] parametrelerine etkisini belirlemektir.Gereç ve Yöntem: Araştırmada 10 adet koyuna 6 mg/kg/gün (deri altı) dozunda danofloksasin 14 gün süresince uygulandı. 0. (Kontrol), 1., 3., 5., 7., 9., 11., 13. ve 15. günler kan örnekleri alındı. Serum 8-OHDG, troponin I ve CK-MB izoenzim düzeyi ELISA okuyucusunda, serum LDH, AST, ALT, ALP, kreatinin ve BUN değerleri otoanalizörde belirlendi. Hemogram parametreleri ise kan hücresi sayım cihazında ölçüldü.Bulgular: Araştırmada 8-OHDG düzeyinde istatistiki değişimler belirlenmezken (P>0,05), troponin I, CK-MB izoenzim ve AST değerinde geçici yükselmeler belirlendi (P<0,05). BUN değerinde istatistiki dalgalanmalar (P<0,05) gözlenirken, WBC, RBC, hemoglobin ve hematokrit değerlerinde düşmeler (P<0,05) ve platelet düzeyinde geçici yükselme (P<0,05) belirlendi.Öneri: Sonuç olarak koyunlara 14 gün danofloksasin uygulamasının sistemik oksidatif strese neden olmadığı, kalp, karaciğer, böbrek ve kemik iliği fonksiyonu üzerine ciddi etkilere neden olmayabileceği ifade edilebilir.
Anahtar Kelime:

Konular: Veterinerlik

Determination of the effect of danofloxacin on 8-hydroxy-2-deoxyguanosine level

Öz:
Aim: The primary aim of this study is to determine the effect of danofloxacin administrations on 8-hydroxy-2-deoxyguanosine (8- OHDG) level, oxidative stress biomarker, in sheep. In addition, to determine on heart [Troponin I, creatine kinase-MB (CK-MB) isoenzyme, lactate dehydrogenase (LDH), aspartate aminotransferase (AST)], liver [Alkaline phosphatase (ALP), alanine aminotransferase (ALT)] and kidney [Blood urea nitrogen (BUN), creatinine] damage biomarkers and hemogram parameters [White blood cell count (WBC), red blood cell count (RBC), platelet count, hemoglobin, hematocrit]. Materials and Methods: In this study, 6 mg/kg/day (Subcutaneous) dose of danofloxacin was applied to 10 sheep for 14 days. Blood samples were taken on day 0 (control), 1, 3, 5, 7, 9, 11, 13 and 15 days. Serum 8-OHDG, troponin I and CK-MB isoenzyme levels were measured with ELISA reader, while serum LDH, AST, ALT, ALP, creatinine and BUN values were determined with autoanalyzer. Hemogram parameters were determined with hemocell counter. Results: In this study, 8-OHDG levels did not change (P>0,05) statistically, while temporal elevations in troponin I, CK-MB isoenzyme and AST levels were determined (P<0,05). Statistical fluctuations (P<0,05) were determined in BUN levels, while decreases in WBC, RBC, hemoglobin and hematocrit values (P<0,05) and temporary increase in platelet level were determined (P<0,05). Conclusion: It can be stated that danofloxacin administration to sheep for 14 days does not cause systemic oxidative stress and does not cause seriously effects to the function of heart, liver, kidney and bone marrow.
Anahtar Kelime:

Konular: Veterinerlik
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Adikwu E, Deo O, 2012. Fluoroquinolones reported hepatotoxicity. Pharmacology & Pharmacy, 3, 328-336.
  • Ayala A, Munoz MF, Arguelles S, 2014. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev, 2014:360438.
  • Ball P, 2000. Safety of the new fluoroquinolones compared with ciprofloxacin. J Chemother, 12, 8-11.
  • Coskun D, Dik B, Korkmaz Y, Canbar R, Er A, Yazar E, 2019. Investigation of cardiotoxic effects of marbofloxacin. Eurasian J Vet Sci, 35, 56-61.
  • Coskun D, Parlak K, Dik B, Faki HE, Bahcivan E, Yazar E, Er A, 2018. Effect of enrofloxacin on the joint fluid/blood oxidative status and organ damage markers. ARRB, 25, 1-7.
  • Dąbrowska N, Wiczkowski A, 2017. Analytics of oxidative stress markers in the early diagnosis of oxygen DNA damage. Adv Clin Exp Med, 26, 155-166.
  • Danese E, Montagnana M, 2016. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med, 4, 194.
  • De Sarro A, De Sarro G, 2014. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem, 8, 371-384.
  • Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, Di Minno MN, 2016. 8-hydroxy-2-deoxyguanosine levels and cardiovascular disease: A systematic review and meta-analysis of the literature. Antioxid Redox Signal, 24, 548-555.
  • Di Minno A, Turnu L, Porro B, Squellerio I, Cavalca V, Tremoli E, Di Minno MN, 2017. 8-hydroxy-2-deoxyguanosine levels and heart failure: A systematic review and metaanalysis of the literature. Nutr Metab Cardiovasc Dis, 27, 201-208.
  • EMA 2019. https://www.ema.europa.eu/documents/mrlreport/ danofloxacin-summary-report-1-committeeveterinary- medicinal-products_en.pdf. Erişim tarihi: 01.06.2019
  • Enoki Y, Ishima Y, Tanaka R, Sato K, Kimachi K, Shirai T, Watanabe H, Chuang VT, Fujiwara Y, Takeya M, Otagiri M, Maruyama T, 2015. Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury. PLoS One, 10:0130248.
  • Hallen J, 2012. Troponin for the estimation of infarct size: what have we learned? Cardiology, 121, 204-12.
  • Heidelbaugh JJ, Holmstrom H, 2013. The perils of prescribing fluoroquinolones. J Fam Pract, 62, 191-197.
  • Ilgin S, Can OD, Atli O, Ucel UI, Sener E, Guven I, 2015. Ciprofloxacin- induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods, 25, 374- 381.
  • Jackson MA, Schutze GE, 2016. The use of systemic and topical fluoroquinolones. Pediatrics, 138, 20162706.
  • Kasai H, Nishimura S, 1984. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucleic Acids Res, 12, 2137-2145.
  • Kirkan S, Ural K, Parin U, Ortlek O, Balikci C, Gultekin M, Karademir U, Akin I, 2018. Submandibular and parotid abscess due to Nocardia sp. and therapy with danofloxacin in sheep. J Hellenic Vet Med Soc, 68, 21-26.
  • Kroese LJ, Scheffer PG, 2014. 8-hydroxy-2'-deoxyguanosine and cardiovascular disease: a systematic review. Curr Atheroscler Rep, 16, 452.
  • Liu HH, 2010. Safety profile of the fluoroquinolones. Drug Saf, 33, 353-369.
  • Martinez M, McDermott P, Walker R, 2006. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet J, 172, 10-28.
  • Milicevic N, Busch CJ, Binder CJ, 2016. Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis. Adv Immunol, 131, 1-59.
  • Munik MS, Ekmekcioglu C, 2015. Prooxidant effects of melatonin: A brief review. Turk J Biol, 39, 832-839.
  • Paredes-Sanchez E, Montiel-Company JM, Iranzo-Cortes JE, Almerich-Torres T, Bellot-Arcis C, Almerich-Silla JM, 2018.
  • Meta-analysis of the use of 8-OHDG in saliva as a marker of periodontal disease. Dis Markers, 2018:7916578. Pilger A, Rudiger HW, 2006. 8-hydroxy-2'-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. Int Arch Occup Environ Health, 80, 1-15.
  • Pouzaud F, Bernard-Beaubois K, Thevenin M, Warnet JM, Hayem G, Rat P, 2004. In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. J Pharmacol Exp Ther, 308, 394-402.
  • Saracoglu A, Temel HE, Ergun B, Colak O, 2009. Oxidative stress-mediated myocardiotoxicity of ciprofloxacin and ofloxacin in juvenile rats. Drug Chem Toxicol, 32, 238-242.
  • Sharma PC, Jain A, Jain S, 2009. Fluoroquinolone antibacterials: A review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm, 66, 587-604.
  • Yazar E, 2018a. Veteriner İlaç ve Aşı A’dan Z’ye, Nobeltip, Istanbul, Türkiye, p: 152.
  • Yazar E, 2018b. Kemoterapötikler, in: Veteriner İlaç Rehberi ve Tedavi El Kitabı, Ed: Yazar E, Nobeltip, Istanbul, Türkiye, pp: 85-161.
  • Yazar E, Tras B, 2001. Effects of fluoroquinolone antibiotics on hepatic superoxide dismutase and glutathione peroxidase activities in healthy and experimentally induced peritonitis mice. Revue Med Vet, 152, 235-238.
  • Yazar E, Tras B, 2002. Free oxygen radicals, antioxidant enzymes and antibiotics. J Turk Vet Med Assoc, 14, 42-44.
  • Yoshida M, Miyajima K, Shiraki K, Ando J, Kudoh K, Nakae D, Takahashi M, Maekawa A, 1999. Hepatotoxicity and consequently increased cell proliferation are associated with flumequine hepatocarcinogenesis in mice. Cancer Lett, 141, 99-107.
  • Yu CH, Liu ZY, Sun LS, Li YJ, Zhang DS, Pan RT, Sun ZL, 2013. Effect of danofloxacin on reactive oxygen species production, lipid peroxidation and antioxidant enzyme activities in kidney tubular epithelial cell line, LLC-PK1. Basic Clin Pharmacol Toxicol, 113, 377-384.
APA COŞKUN D, CANBAR R, KORKMAZ Y, DIK B, ER A, YAZAR E (2019). Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. , 224 - 229. 10.15312/EurasianJVetSci.2019.245
Chicago COŞKUN Devran,CANBAR Rahmi,KORKMAZ Yasemin,DIK BURAK,ER Ayşe,YAZAR Enver Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. (2019): 224 - 229. 10.15312/EurasianJVetSci.2019.245
MLA COŞKUN Devran,CANBAR Rahmi,KORKMAZ Yasemin,DIK BURAK,ER Ayşe,YAZAR Enver Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. , 2019, ss.224 - 229. 10.15312/EurasianJVetSci.2019.245
AMA COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. . 2019; 224 - 229. 10.15312/EurasianJVetSci.2019.245
Vancouver COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. . 2019; 224 - 229. 10.15312/EurasianJVetSci.2019.245
IEEE COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E "Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi." , ss.224 - 229, 2019. 10.15312/EurasianJVetSci.2019.245
ISNAD COŞKUN, Devran vd. "Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi". (2019), 224-229. https://doi.org/10.15312/EurasianJVetSci.2019.245
APA COŞKUN D, CANBAR R, KORKMAZ Y, DIK B, ER A, YAZAR E (2019). Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. Eurasian Journal of Veterinary Sciences, 35(4), 224 - 229. 10.15312/EurasianJVetSci.2019.245
Chicago COŞKUN Devran,CANBAR Rahmi,KORKMAZ Yasemin,DIK BURAK,ER Ayşe,YAZAR Enver Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. Eurasian Journal of Veterinary Sciences 35, no.4 (2019): 224 - 229. 10.15312/EurasianJVetSci.2019.245
MLA COŞKUN Devran,CANBAR Rahmi,KORKMAZ Yasemin,DIK BURAK,ER Ayşe,YAZAR Enver Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. Eurasian Journal of Veterinary Sciences, vol.35, no.4, 2019, ss.224 - 229. 10.15312/EurasianJVetSci.2019.245
AMA COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. Eurasian Journal of Veterinary Sciences. 2019; 35(4): 224 - 229. 10.15312/EurasianJVetSci.2019.245
Vancouver COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi. Eurasian Journal of Veterinary Sciences. 2019; 35(4): 224 - 229. 10.15312/EurasianJVetSci.2019.245
IEEE COŞKUN D,CANBAR R,KORKMAZ Y,DIK B,ER A,YAZAR E "Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi." Eurasian Journal of Veterinary Sciences, 35, ss.224 - 229, 2019. 10.15312/EurasianJVetSci.2019.245
ISNAD COŞKUN, Devran vd. "Danofloksasinin 8-hidroksi-2-deoksiguanozin düzeyine etkisinin belirlenmesi". Eurasian Journal of Veterinary Sciences 35/4 (2019), 224-229. https://doi.org/10.15312/EurasianJVetSci.2019.245